Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.

Bekoz, H.; Karadurmus, N.; Paydas, S.; Turker, A.; Toptas, T.; Tuglular, T.; Sonmez, M.; Gulbas, Z.; Tekgunduz, E.; Kaya, A.; Ozbalak, Mustafa; Tastemir, N.; Kaynar, L.; Yildirim, R.; Karadogan, I.; Arat, M.; Tanrikulu, F.; Ozkocaman, V.; Abali, H.; Turgut, M.; Yuksel, M.; Ozcan, M.; Dogu, M.; Hacioglu, S.; Barista, I.; Demirkaya, M.; Koseoglu, F.; Toprak, S.; Yilmaz, M.; Demirkurek, H.; Demirkol, O.; Ferhanoglu, B.

doi:10.1093/annonc/mdx341

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.

Bekoz H., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T. F., ...More

Annals of oncology : official journal of the European Society for Medical Oncology, vol.28, no.10, pp.2496-2502, 2017 (SCI-Expanded)

Publication Type: Article / Article
Volume: 28 Issue: 10
Publication Date: 2017
Doi Number: 10.1093/annonc/mdx341
Journal Name: Annals of oncology : official journal of the European Society for Medical Oncology
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.2496-2502
Keywords: Hodgkin lymphoma, resistant/relapsed disease, programmed death 1 (PD-1) blocker, nivolumab, BRENTUXIMAB VEDOTIN, PD-1 BLOCKADE
Istanbul University Affiliated: Yes

Abstract

Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile.